News

A protein called Wnt5a seems to be involved in the development of chronic obstructive pulmonary disease (COPD), according to a study published recently in the Journal of Experimental Medicine. This finding may be a path to the development of new therapies targeting this protein. The study was published under…

The chief executive of education for health and chair of the UK Inhaler Group, Monica Fletcher, will join a panel of speakers at the Asthma & COPD 2017 conference March 29-30 in London. Fletcher will discuss inhalers and patient compliance in the treatment of asthma and chronic obstructive…

Women who have never smoked are still vulnerable to develop chronic obstructive pulmonary disease (COPD). African-American women are especially susceptible to the disease, researchers at the University of Toronto found. The results of the study, “COPD in a Population-Based Sample of Never-Smokers: Interactions among Sex, Gender, and…

InMed Pharmaceuticals announced that its research and development program using cannabinoids for the treatment of chronic obstructive pulmonary disease (COPD) has made new progress. The company initiated its COPD program in June 2015, leveraging its bioinformatics analysis tool to identify the targets and potential active compounds that could be used…

The University of Newcastle (UON) in Australia was awarded a total of $10.8 million from the National Health and Medical Research Council (NHMRC) to support 14 projects and one Career Development Fellowship. Of the total, $3.4 million will be dedicated to help develop new treatments for asthma and chronic obstructive…

Newly updated chronic obstructive pulmonary disease (COPD) management recommendations from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) now include the reduction in bronchoscopic lung volume through the use of endobronchial valves as a treatment option for patients suffering with advanced emphysema and absence of collateral ventilation. The new recommendations are…

GlaxoSmithKline (GSK), together with Innoviva, recently announced GSK submitted a New Drug Application (NDA) with the U.S. FDA for the triple combination therapy FF/UMEC/VI (fluticasone furoate/umeclidinium/vilanterol) to treat chronic obstructive pulmonary disease (COPD). GSK announced earlier this year that it was planning to advance the timing of the filing with…

People with chronic obstructive pulmonary disease (COPD) often find it difficult to breathe, sometimes feeling like they breathing through a straw. To help raise awareness for this respiratory disease, Royal Philips announced it has joined the COPD Foundation and the family of the late Leonard Nimoy, who died in 2015,…

Confirmation of a diagnosis of chronic obstructive pulmonary disease (COPD) using pulmonary function testing is associated with not only a decreased risk of death, but fewer admissions to the hospital due to COPD. The study reporting the findings, “Outcomes of patients with chronic obstructive pulmonary disease diagnosed with or…

Propeller Health recently announced that its Propeller platform has received 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) for use with Breo Ellipta, GSK’s dry powder inhaler. On Dec. 1, 2015, Propeller, based in Madison, Wisconsin, and GlaxoSmithKline, headquartered in London, entered into a research and development agreement…